Arena Pharmaceuticals, Inc. (ARNA)
(Delayed Data from NSDQ)
$79.49 USD
-0.61 (-0.76%)
Updated Feb 25, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.41% |
| 2 | Buy | 17.88% |
| 3 | Hold | 9.48% |
| 4 | Sell | 5.03% |
| 5 | Strong Sell | 1.87% |
| S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
D Value F Growth C Momentum F VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
View All Zacks #1 Ranked Stocks
Zacks News
Arena (ARNA) Q4 Earnings Miss Estimates, Pipeline Progresses
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) misses bottom-line estimates for fourth-quarter 2020. It initiates new study to evaluate etrasimod in patients with eosinophilic esophagitis.
DVAXNegative Net Change MRNAPositive Net Change ARNANegative Net Change LXRXNegative Net Change
biotechs earnings
Drug/Biotech Stock Q4 Earnings on Feb 23: JAZZ, ARNA & More
by Kinjel Shah
Let us take a look at five small biotech companies, JAZZ, ARNA, HALO, EPZM, ESPR, which are gearing up for their earnings release.
ARNANegative Net Change JAZZNegative Net Change HALONegative Net Change ESPRNegative Net Change EPZMNegative Net Change
biotechs
Arena (ARNA) Q3 Earnings Top, Stock Down on Eczema Study Data
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) beats bottom-line estimates for third-quarter 2020. Mid-stage atopic dermatitis study on etrasimod fails to meet primary endpoint but phase III study may start soon.
ARNANegative Net Change EBSNegative Net Change RGENNegative Net Change MGENNegative Net Change
biotechs earnings
Arena (ARNA) Starts Phase II Alopecia Areata Study on Etrasimod
by Zacks Equity Research
Arena (ARNA) doses first patients in a phase II study evaluating etrasimod in patients with alopecia areata.
REGNNegative Net Change PFEPositive Net Change ARNANegative Net Change ABBVNegative Net Change
biotechs
Arena Pharmaceuticals (ARNA) Q2 Loss Narrower Than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) beats bottom-line estimates for the second quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.
ARNANegative Net Change EBSNegative Net Change HZNPNegative Net Change UMRXPositive Net Change
biotechs earnings
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
INCYNegative Net Change ARNANegative Net Change PRGONegative Net Change PETQPositive Net Change
pharmaceuticals
BioMarin (BMRN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
BioMarin (BMRN) is likely to provide an update on the sales of its key drugs Vimizim, Kuvan and others as well as how the pipeline has progressed when it reports Q2 earnings.
BMRNNegative Net Change INCYNegative Net Change ARNANegative Net Change BLUEPositive Net Change
biotechs
Cyclacel (CYCC) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on its pipeline progress when Cyclacel (CYCC) reports Q2 results.
ARNANegative Net Change TBIONegative Net Change CYCCNegative Net Change QURENegative Net Change
biotechs earnings
What's in Store for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Novavax (NVAX) is developing a coronavirus vaccine. The company is likely to provide an update on the vaccine's progress on its Q2 earnings call.
SNYNegative Net Change INCYNegative Net Change ARNANegative Net Change NVAXNegative Net Change
biotechs
Is a Beat in Store for Dynavax (DVAX) This Earnings Season?
by Zacks Equity Research
Dynavax (DVAX) is actively pursuing development of coronavirus vaccine through collaborations. Investors are likely to focus on progress of vaccine programs on Q2 earnings call.
DVAXNegative Net Change PFEPositive Net Change INCYNegative Net Change ARNANegative Net Change
pharmaceuticals
What's in Store for CRISPR (CRSP) This Earnings Season?
by Zacks Equity Research
CRISPR Therapeutics (CRSP) is developing its lead gene-editing candidate for thalassemia and sickle cell disease. The company is expected to provide an update on its progress on the earnings call.
INCYNegative Net Change ARNANegative Net Change VRTXNegative Net Change CRSPNegative Net Change
biotechs
Moving Average Crossover Alert: Arena Pharmaceuticals
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
ARNANegative Net Change
medical
Is Arena (ARNA) Stock a Solid Choice Right Now?
by Zacks Equity Research
Arena (ARNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
ARNANegative Net Change
medical
Arena Pharmaceuticals (ARNA) Q1 Loss Narrower Than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) beats bottom-line estimates in the first quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.
UTHRNegative Net Change IMMUNegative Net Change ARNANegative Net Change SGENNegative Net Change
biotechs earnings
United Therapeutics (UTHR) Down Despite Q1 Earnings Beat
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates for both earnings and sales in first quarter. It expects a reduction in new patient starts in the future quarters. Stock down.
MDTNegative Net Change LLYNegative Net Change UTHRNegative Net Change ARNANegative Net Change
pharmaceuticals
Arena's Pipeline Holds Promise, Plunging Revenues a Concern
by Zacks Equity Research
Arena (ARNA) has sufficient funds to support its pipeline progress. However, competitive targeted indications and plunging revenues raise concerns.
REGNNegative Net Change ARNANegative Net Change
biotechs
Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status
by Zacks Equity Research
The FDA grants fast track status to Arena's (ARNA) early-stage candidate, APD418, for the treatment of decompensated heart failure.
CHRSNegative Net Change ARNANegative Net Change AVXLPositive Net Change UTHRNegative Net Change
biotechs
Arena (ARNA) Expands Strategic Deal With Beacon Discovery
by Zacks Equity Research
Arena (ARNA) enters into multi-year strategic partnership with Beacon Discovery to discover and develop therapies targeting multiple immune and inflammatory indications.
CHRSNegative Net Change AGENNegative Net Change ARNANegative Net Change UTHRNegative Net Change
biotechs
Arena Pharmaceuticals' (ARNA) Q3 Loss Widens, Revenues Beat
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the third quarter of 2019 while revenues beat estimates.
VRTXNegative Net Change ARNANegative Net Change ALKSNegative Net Change UTHRNegative Net Change
biotechs earnings
United Therapeutics (UTHR) Q3 Earnings & Sales Top, Stock Up
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates on both fronts in the third quarter. Stock rises in response
LLYNegative Net Change MDTNegative Net Change ARNANegative Net Change UTHRNegative Net Change
pharmaceuticals
United Therapeutics' Trevyent NDA for PAH Accepted by FDA
by Zacks Equity Research
United Therapeutics (UTHR) announces acceptance of Trevyent NDA by the FDA for pulmonary arterial hypertension.
MDTNegative Net Change MNKDNegative Net Change ARNANegative Net Change UTHRNegative Net Change
pharmaceuticals
Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the second quarter of 2019 while revenues are in line.
BGNENegative Net Change ARNANegative Net Change UTHRNegative Net Change GHNegative Net Change
biotechs earnings
United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Down Y/Y
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates on both fronts in the second quarter. Loss of exclusivity for Adcirca and lower sales of Remodulin hurts sales.
LLYNegative Net Change NVSNegative Net Change ARNANegative Net Change UTHRNegative Net Change
pharmaceuticals
Analysts Estimate Arena Pharmaceuticals (ARNA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ARNANegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Arena Pharmaceuticals (ARNA) Upgraded to Buy: Here's Why
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ARNANegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank